Childhood Immunisation is the use of vaccines to stimulate protective immune responses against infectious diseases during childhood. Vaccination exposes the immune system to an antigen or antigenic information in a form designed to produce immunological memory without causing the disease in the same way as natural infection. Subsequent exposure to the pathogen can then trigger a faster and more effective immune response. Childhood immunisation includes primary doses and, where necessary, later booster doses that maintain or restore protection.
Vaccines can protect the vaccinated child directly and can also reduce transmission within communities, thereby helping protect people who cannot be vaccinated or who do not develop adequate immunity. WHO and national immunisation programmes regard vaccination as one of the major interventions for preventing serious childhood infections.
Different vaccines use different biological approaches. Some contain weakened forms of organisms, some use inactivated organisms or components, and others use purified proteins, polysaccharides, viral vectors or nucleic-acid-based technologies. The immune system recognises vaccine-derived antigens and develops adaptive immune responses involving antibodies and immune memory. The precise type and duration of immunity vary between vaccines and pathogens, which is why some vaccines require multiple primary doses and others require later boosters. Vaccine schedules are designed around the age at which disease risk, immune responsiveness and interference from maternal antibodies make particular doses most useful. The schedule is therefore a population-level programme based on epidemiological and immunological evidence rather than an arbitrary timetable.
Childhood Immunisation schedules differ between countries because disease prevalence, healthcare policy, vaccine availability and local epidemiology differ. In England, the NHS schedule includes vaccines during infancy and childhood, with examples including the 6-in-1 vaccine, rotavirus vaccine, MenB, pneumococcal vaccination, measles-mumps-rubella-related vaccination and later vaccines for particular age groups. Schedules can change as new evidence, vaccines and public-health priorities emerge, so current national guidance should be consulted rather than relying on an old schedule. The NHS advises that vaccines should ideally be given on time but that many missed vaccinations can be caught up through appropriate healthcare services.
Immunisation protects against diseases that can cause severe complications, disability or death. The benefits depend on the specific vaccine and pathogen but can include prevention of invasive infection, neurological complications, pneumonia, meningitis and other serious outcomes. Vaccination also reduces circulation of infectious organisms, creating indirect protection for susceptible individuals. High population coverage is particularly important for infections capable of spreading rapidly because individual protection alone does not necessarily prevent community transmission. WHO identifies immunisation as an important component of preventing child mortality and promoting healthy growth and development, alongside nutrition, sanitation and timely treatment of illness.
Vaccine safety is assessed through clinical trials and continuing post-authorisation surveillance. Common reactions such as pain at the injection site, mild fever or temporary irritability reflect immune activation and generally resolve without serious consequences. Rare serious adverse events can occur, which is why vaccination programmes include systems for monitoring safety and investigating unusual events.
The risk-benefit assessment is disease-specific and depends on the probability and severity of the infection being prevented, the effectiveness and safety profile of the vaccine and the characteristics of the individual receiving it. A vaccine does not need to produce zero adverse effects to provide a substantial public-health benefit; the relevant comparison is between vaccination risks and the risks associated with the disease and its complications.
Missed doses do not usually mean that an entire vaccination course must be restarted. Catch-up schedules can be used to provide outstanding protection according to the person's age and previous vaccination history. Some vaccines require specific intervals between doses, while others can be administered at different ages according to national recommendations. Medical conditions, previous severe allergic reactions and immune status can affect whether a particular vaccine is appropriate, so individual exceptions require clinical assessment. The NHS specifically advises families to contact their GP practice if a child has missed vaccinations or an appointment.
Childhood Immunisation has a major relationship with childhood infections because vaccination changes both individual susceptibility and population transmission. Some diseases become uncommon where coverage is high but can return when immunity falls, allowing outbreaks to occur. Immunisation also complements rather than replaces other infection-control measures such as hygiene, ventilation, safe water, appropriate diagnosis and treatment. Vaccines are not effective against every infectious disease, and protection varies according to the pathogen, vaccine and individual immune response. Consequently, an immunised child can still occasionally develop an infection against which they have been vaccinated, but vaccination can substantially reduce the probability of infection or severe disease for many vaccine-preventable conditions.
A common misconception is that immunisation and natural infection are equivalent ways to obtain immunity. Natural infection can cause serious disease and complications, whereas vaccination aims to generate protective immunity without requiring the person to experience the disease itself. Another misconception is that missing one appointment necessarily eliminates the possibility of protection; many schedules provide catch-up opportunities. Childhood Immunisation is therefore both an individual medical intervention and a population-health measure. Its effectiveness depends on appropriate vaccine selection, correct scheduling, high coverage, surveillance, communication and continued access to healthcare. The programme evolves over time as epidemiology, vaccine technology and evidence change.
